Join N4 Pharma Plc for a pre-recorded webinar on their recent Collaboration Agreement with SRI International Inc. Available on 7 May 2024 at 10:00 BST...

N4 Pharma Plc partners with SRI International to combine Nuvec® with FOX Three MGS, aiming to enhance nucleotide therapies for cancer and vaccines...

N4 Pharma Plc (LON:N4P) unveils its audited results for 2023, showcasing advancements in its innovative Nuvec® delivery system for cancer treatments and vaccines...

N4 Pharma Plc (LON:N4P) updates on successful oral delivery research for Nuvec® system, showing potential for cancer treatment and vaccines. CEO Nigel Theobald shares insights...

N4 Pharma Plc provides an update on its in vitro siRNA research work, showcasing the versatility of their Nuvec® delivery system for cancer treatments...

N4 Pharma Plc announces the granting of a patent for its Nuvec® delivery system in India, adding to its global portfolio of granted patents...

N4 Pharma's subsidiary, Nanogenics, has signed a contract to prepare its ECP105 product for pre-clinical studies in Glaucoma treatment...

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, has provided a further successful update on its ongoing..

N4 Pharma Plc (LON: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a positive update on its ongoing oral delivery..

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an encouraging update on its ongoing in vitro siRNA..

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced the launch of the N4 Pharma Interactive Investor Hub...

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that an updated investor presentation incorporating the Company’s acquisition..

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for oncology, gene therapy and vaccines, has announced the acquisition of a controlling interest, through a..

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced two operational updates. Granting of further US patent The..

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce it will be supporting the University..